Development of HIV 1 antigenemia during treatment with azidothymidine (AZT) : follow-up of 90 patients for a year

Berlie, H.C.; Berlioux, J.; Daguet, G.L.

Pathologie-Biologie 37(5 Part 2): 685-689

1989


ISSN/ISBN: 0369-8114
PMID: 2571970
Document Number: 334931
VIH 1 antigenaemia has a significant value in the follow-up of patients treated with AZT. This study of 90 patients (55 ARC - 35 AIDS), each receiving AZT for more than a year, 200 mg every 4 hours, demonstrates the prognosis value of antigenaemia at Day 0, as well as its therapeutic indication value. However, at term and under this treatment, the significance of this virological data has to be reconsidered. Various kinetic patterns are described according to the clinical status and the CD4+ cells count.

Document emailed within 1 workday
Secure & encrypted payments